GGHC
IOVA icon

Gilder Gagnon Howe & Co’s Iovance Biotherapeutics IOVA Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-139,080
Closed -$3.41M – 294
2019
Q2 		$3.41M Buy
+139,080
New +$2.09M 0.03% 188

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Gilder Gagnon Howe & Co's IOVA Position: Q3 2019 in Review

Gilder Gagnon Howe & Co sold out of Iovance Biotherapeutics (IOVA) in Q3 2019, closing a stake of 139,080 shares — an estimated $3.41M sold.

Gilder Gagnon Howe & Co first reported a position in IOVA in Q2 2019 and held it in 1 quarter. The position peaked at $3.41M in Q2 2019. 173 funds tracked by Wall St. Rank hold IOVA as of Q3 2019.

  • Gilder Gagnon Howe & Co reported no remaining Iovance Biotherapeutics position as of Q3 2019 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 139,080 Iovance Biotherapeutics shares in Q3 2019, an estimated $3.41M.
  • Gilder Gagnon Howe & Co first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Iovance Biotherapeutics position peaked at $3.41M in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2019.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2019, filed 14 Nov 2019.